Table S2 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

MRM Quantification Parameters</p

Table S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Table shows Tabulated cell growth inhibition data for NCI-N87 and MDA-MB231 cells in monoculture and coculture when treated with ADCs T-16, T-17, and T-18</p

Figure S4 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Figure shows In vitro activity of NaPi2b ADCs X-BG and X-19 and payload 4 in the OVCAR3 cell line</p

Figure S5 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Figure shows Plasma stability comparing indole-linked ADC T-13 to N10-linked ADC T-BH</p

Table S9 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Table shows Cytotoxicity Data for Platforms 18 vs 19</p

Table S7 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Table shows Cytotoxicity comparisons between Biaryl PBD ADCs vs DGN549 ADCs</p

Table S6 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Table shows Cytotoxicity comparisons between Biaryl PBD payloads 4 and 20 vs IGN 2</p

Figure S6 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Figure shows comet assay results</p

Table S3 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Table shows Payload in vitro potency in various cell lines.</p

Figure S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Figure shows Cytotoxicity of Mesothelin ADCs M-16, M-17, and M-19 in NCI-N87 cell line</p